Key Stats for Merck Stock
- Current Price: $113.15
- 52-Week Range: $73.31 to $125.14
- Street Mean Target: ~$130
- TIKR Model Target Price: ~$150
- Implied Upside (TIKR): ~34%
- Dividend Yield: 3.0%
Value your favorite stocks like Merck & Co. with 5 years of analysts’ forecasts using TIKR’s new Valuation Model (It’s free) >>>
Keytruda Beat, Winrevair Surged, and Merck Raised Guidance. The Stock Barely Moved
Merck (MRK) reported Q1 2026 results on April 30th that were, by most measures, genuinely strong. Revenue came in at $16.3 billion, up about 5% year over year and ahead of estimates by nearly 3%. Keytruda, the world’s top-selling cancer drug, generated $8.0 billion in sales for the quarter, up 12%, and beat the consensus estimate of $7.7 billion.
Winrevair, Merck’s treatment for pulmonary arterial hypertension that launched in mid-2024, delivered $525 million in sales, up 88%, ahead of the $487 million analysts had penciled in.
Merck raised its full-year adjusted EPS outlook to $5.04 to $5.16 and narrowed its revenue guidance to $65.8 to $67 billion.
The reason the headlines looked messy was a $9 billion upfront charge tied to Merck’s acquisition of Cidara Therapeutics, a biotech developing a long-acting antifungal. That charge resulted in a large GAAP loss for the quarter, and even the adjusted EPS figure was deeply negative.
The Street had anticipated this, which is why estimates for the quarter already reflected a loss, and Merck beat those expectations by around 13% on an adjusted basis.
On the day of the report, the stock rose nearly 3%. The underlying operating business performed well. The reported loss was an accounting reflection of a deliberate strategic investment, not a sign the business is struggling.
See analysts’ growth forecasts and price targets for Merck & Co. (It’s free) >>>
The Financials Are Strong. The Market Is Already Looking Past 2028
Looking at the revenue and margin picture over the past five years, the trajectory here is solid. Revenue has grown from $48.7 billion in 2021 to $65.0 billion in 2025, while operating margins have expanded from around 29% to nearly 38% over the same period. Gross margins have remained above 72% throughout, reflecting the pricing power and product mix associated with a best-in-class oncology franchise.
The reason this business still trades at around 13 times forward earnings, despite those margin levels, is straightforward. Keytruda represents more than half of Merck’s total revenue, and its core US patent expires in 2028. When a single drug that size faces biosimilar competition, the market tends to apply a discount well before the event.
Merck is actively working to manage that transition through Keytruda QLEX, a new subcutaneous formulation designed to capture a meaningful share of the existing patient base ahead of biosimilar entry, with a goal of 30-40% conversion by 2028. Meanwhile, GARDASIL, the company’s HPV vaccine, has seen its China business effectively collapse, with revenues in that market down 47% after Merck halted shipments into the country in early 2026.
The company knows what it is up against, and the strategy to address it is visible. Winrevair is growing fast. FDA approval of IDVYNSO, a new HIV-1 regimen, adds another non-oncology pillar.
The pipeline includes near-term decisions on WELIREG in renal cell carcinoma, multiple PDUFA dates through the back half of the year, and, per CEO Robert Davis, roughly $70 billion in commercial opportunities by the mid-2030s. The pipeline is real. The question is whether it is enough to flatten what the bears are calling a cliff.
See historical and forward estimates for Merck stock (It’s free!) >>>
What a Fair Price for MRK Actually Looks Like From Here
TIKR’s valuation model targets around $150 for MRK, implying roughly 34% total return over about five years, or around 6% annualized. When you add the 3% dividend yield, the total annual return in the mid-case lands closer to 9%.
The model is deliberately conservative on revenue, assuming essentially flat top-line growth through 2030, reflecting the Keytruda patent cliff. Net income margins are expected to expand to around 33% as the product mix improves, and EPS is expected to compound modestly as buybacks absorb some of the earnings-per-share math.
What the Bulls Are Betting On:
- Keytruda’s growth runway is longer than the patent date implies. The drug continues to expand into earlier-stage indications, and the QLEX subcutaneous formulation gives Merck a tool to retain patients even as the IV formulation faces biosimilar competition. Management has expressed growing confidence in defending additional patents into 2029.
- Winrevair is a genuine second act. Growing 88% on a $525 million base, in a rare disease with significant unmet need, this drug has multi-billion-dollar potential and is still in the early phases of adoption.
- The valuation prices in a lot of bad news already. At around 13 times forward earnings with a 3% yield and 76% gross margins, MRK is priced more like a business in secular decline than one with a deep pipeline and the ability to generate consistent free cash flow through and beyond the patent transition.
- M&A is actively building the next chapter. Cidara, Terns, and other recent deals reflect a management team that is not waiting for the cliff to arrive before acting. The pipeline investment is happening now.
What the Bears Are Watching:
- Keytruda is over 50% of sales, and the clock is running. Even with every mitigation strategy working as planned, Merck faces a meaningful revenue disruption in 2028 and 2029 that the current pipeline may not fully offset on a dollar-for-dollar basis.
- Three Phase 3 trial failures in oncology recently. LITESPARK-012, KEYNOTE-975, and KEYNOTE-866 all missed, raising questions about how much of the pipeline will actually convert into approved products and meaningful revenue.
- GARDASIL’s China business is effectively gone. With revenues in China down 47% and shipments halted, a meaningful contributor to the top line has been removed from the model indefinitely.
- Acquisitions are adding debt. The Cidara and Terns deals push net debt closer to $50 billion. At around 1.45 times EBITDA today, that is manageable, but the balance sheet has less flexibility than it did two years ago.
Should You Invest in Merck’s?
Merck is trading at a deep discount to its historical multiples for a reason, and that reason is not irrational. The Keytruda patent cliff is real, the timeline is known, and the revenue exposure is significant.
Investors who buy MRK today are betting that the combination of Winrevair’s growth, pipeline execution, and strategic M&A is enough to carry the company through 2028 and 2029 without a prolonged earnings trough on the other side.
What makes that bet reasonably interesting at current levels is the valuation cushion. A 3% dividend, around 13 times forward earnings, and a TIKR model that targets roughly $150 using conservative flat revenue assumptions all suggest the market has already priced in a fairly pessimistic scenario.
If Merck converts even a portion of the $70 billion in pipeline opportunities management has outlined, the current price will look like it underestimated the company’s ability to manage through the transition.
The next major signpost is the WELIREG plus Keytruda adjuvant decision in renal cell carcinoma expected in June, which will be an early read on whether the pipeline diversification story has legs.
See analysts’ growth forecasts and price targets for Merck stock (It’s free!) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
